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Large granular lymphocyte (LGL) leukemia is a rare clonal disease
characterized by a persistent increase in the number of CD8+
cytotoxic T cells or CD16/56+ natural killer (NK) cells. It is associated
with recurrent infections, severe cytopenias and autoimmune
diseases. JAK/STAT pathway activation, deregulation of pro-
apoptotic pathways (sphingolipid and FAS/FAS ligand) and activation
of pro-survival signaling pathways (PI3K/AKT and RAS) are known
hallmarks of LGL leukemia. Activating somatic STAT3 mutations have
been reported in the SH2 domain (30–70% of cases),1–3 and in the
DNA-binding or coiled-coil domain (2%).4 STAT5Bmutations are more
rare, but typical of CD4+ T-LGL leukemia cases.5–7 The JAK/STAT
pathway can also be activated by non-mutational mechanisms such
as increased interleukin-6 (IL-6) secretion and epigenetic inactivation
of JAK-STAT pathway inhibitors.8 Indeed, aberrant STAT signaling is
observed in almost all LGL leukemia patients irrespective of the
presence of JAK/STAT mutations.9
To characterize the genomic landscape of LGL leukemia, we
performed whole-exome sequencing (Supplementary Methods
and Supplementary Figure 1) from 19 paired tumor-control
samples derived from untreated LGL leukemia patients including
conventional CD8+ (n= 13) T-cell cases, and more rare CD4+ or
CD4+CD8+ T-cell cases (n= 3), and NK LGL leukemias (n= 3;
Supplementary Table 1). Eleven STAT-mutation-negative patients
were included for identiﬁcation of new driver mutations. All
sequenced samples were highly puriﬁed sorted cell populations
(either CD8+ or CD4+ T cells or NK cells), and T-cell receptor Vbeta
analysis conﬁrmed monoclonal expansions in the tumor fractions
of T-cell cases (see Supplementary Methods and Supplementary
Table 1). The average sequencing coverage in the tumor samples
was 32x (Supplementary Figure 2). Both the coverage and
the number of raw called variants were similar in tumor and
control samples. After selecting high conﬁdence variants (see
Supplementary Methods), and ﬁltering out variants already
described in human populations single nucleotide polymorphism
database and/or with allele frequency higher than 5% in exome
aggregation consortium exomes, 28 508 somatic variants in
16 518 genes were identiﬁed in the whole cohort with a high
prevalence of C4T and G4A transversions (Supplementary
Figure 3A). Next, among high conﬁdence and rare variants, we
selected 370 variants in 347 genes with a strong predicted
functional impact (Supplementary Methods and Supplementary
Table 2). The observed differences in numbers of somatic
mutations (range 5–40, average 20) and genes involved (range
4–41, 19) per patient were not because of coverage differences
(Supplementary Figure 3B). A slight tendency toward more
mutated genes per patient in STAT-mutation-positive (22.9 in
average) versus negative patients (18.4 in average) was noticed.
Sanger sequencing validations of somatic variants were obtained
in 14 genes (Supplementary Table 3 and Supplementary Figure 4)
being recurrent or prioritized according to functional criteria and/
or connections emerged by integrated pathway-derived networks.
The positions of the mutations in protein domains of selected
genes are shown in Supplementary Figure 5.
In addition to STAT3 (all in CD8+ T-LGL) and STAT5B (CD4+ and
CD8+ cases) mutations (in 8/19 patients, 42%), 14 other genes had
recurrent mutations including transcriptional/epigenetic regulator,
tumor suppressor and cell proliferation genes (Figure 1a and 2a).
KMT2D has been linked to lymphomagenesis10 and found to be
frequently mutated in other cancers. Mutations of PCLO, a calcium
sensor-regulating cAMP-induced exocytosis, have been previously
reported in diffuse large B-cell lymphoma. FAT4 is an upstream
regulator of stem cell genes both during development and cancer,
functioning as a tumor growth suppressor via activation of Hippo
signaling. It was previously found recurrently mutated in human
cancers, including leukemias. Also the other recurrently mutated
gene, ARL13B, is linked to Hippo signaling. It encodes a small
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GTPase of primary cilia whose role in cell cycle control has recently
been recognized, and they crosstalk with several signaling
pathways including Hippo. ARL13B and FAT4 genes were mutated
in a mutually exclusive way. Additional non-recurrent somatic
mutations of YAP1 and of its inhibitor AMOTL1 point toward an
involvement of Hippo signaling deregulation in LGL leukemia.
When comparing the mutation proﬁle between three different
phenotypic LGL subgroups, qualitative and quantitative differ-
ences were observed, although the clinical characteristics of
patients did not markedly differ (see details in Supplementary
Results and Supplementary Table 1). Interestingly, higher mutation
burden was observed in CD4+ T-LGL leukemia cases (Figure 2b).
As the sequencing depth across samples did not vary signiﬁcantly
(Supplementary Figure 3), the differences in mutation load
likely reﬂect a different natural history of the LGL phenotypes.
Cytomegalovirus-derived stimulation and restricted usage of
T-cell receptor Vβ has been associated with CD4+ T-LGL cases,11
and this could relate to the higher number of mutations.
In the CD4+ group, only STAT5B and HRNR genes had recurrent
mutations (Figure 1b). HRNR is a calcium-binding protein involved
in hematopoietic progenitor cell differentiation, and it is mutated,
ampliﬁed or overexpressed in many cancers. In NK LGL leukemias
(all STAT-mutation-negative), 31 genes harbored somatic muta-
tions including several ‘cancer genes’ such as KRAS, PTK2, NOTCH2,
CDC25B, HRASLS, RAB12, PTPRT and LRBA.
Next, a custom knowledge-based ‘systems genetic’ approach,
reminiscent of strategies recently implemented to interpret
genome-wide transcriptome deregulation in cancer,12,13 provided
the functional prioritization of mutated genes. As mutations
hitting different genes can drive a similar phenotype in different
patients and concur to it if present in the same patient, we
reconstructed a pathway-derived meta-network depicting direct
interactions and functional relations between genes somatically
mutated in LGL leukemias. We identiﬁed 119 KEGG and 426
Reactome pathway-derived networks, each including at least one
of the 347 previously prioritized mutated genes associated to high
conﬁdence, rare and high-impact variants. The union of all path-
derived networks generated a meta-network with 118 (34%)
mutated genes, giving a non-redundant representation of
functional relations, based on direct interactions between
somatically mutated genes. Remarkably, 47 mutated genes were
directly connected to at least another mutated gene in 18
multigene components (groups of genes whose products directly
interact, that is, encode proteins taking part in the same molecular
complex or regulating each other). Considering co-participation of
mutated genes in pathways including STAT genes as additional
functional link, seven multigene components connected by direct
relations and three isolated genes converged into a component of
26 genes. In this reconstructed LGL leukemia network (Figure 2c
and Supplementary Figure 6), 61 somatically mutated genes
(occurring in many cases only in one sample) preferentially fall
into a limited number of highly connected pathways, and in this
manner collectively form a functional module hit by somatic
mutations in LGL leukemia. The largest network component
included 24 mutated genes either directly linked to STAT genes, to
their neighbors and/or participating in pathways including STAT
genes (Figure 2c). Beyond JAK-STAT signaling, the ‘STAT-related
component’ included genes intervening in several other con-
nected paths such as acute and chronic myeloid leukemia, ErbB,
HIF-1, insulin, T-cell receptor and VEGF signaling pathways. In 16
out of 19 patients, at least one gene of this group was mutated
with some patients showing more than one hit in the gene group.
For instance, one STAT-mutation-negative CD4+ patient presented
with mutated alleles in three genes of the component (CD40LG, F8
and PLA2G4C). The similar variant allele frequency values of the
validated variants support their co-presence in the dominant LGL
leukemic clone (Supplementary Table 3). Altogether, 8 of 11 STAT-
mutation-negative patients carried validated somatic mutations in
at least one of the ‘STAT-related component’ genes, such as in
FLT3, KRAS, ADCY3, ANGPT2 and PTK2. These mutated genes also
connect the STAT component to the MAPK-Ras-ERK (Figure 2c)
pathway and to the IL-15, all known to be deregulated in LGL
Figure 1. Recurrent somatic mutations in LGL leukemia patients. (a) The table indicates the genes that carry somatic variants in more than one
patient, with a color code showing STAT3 and STAT5B status and classiﬁcation of patients. (b) Recurrently mutated gene sets found only in
STAT-mutation-negative patients (STAT− ), only in STAT-mutation-positive patients (STAT+) or in both groups. (c) Recurrently mutated genes
that are found only in one or are shared among patient classes (CD8+, CD4+/CD4+CD8+ and NK+).
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leukemia.14 For example, PTK2 is a non-receptor protein-tyrosine
kinase, which is highly expressed in T cells and it regulates several
processes, including cell cycle progression, cell proliferation and
apoptosis, activation of numerous pathways such as PI3K/AKT
signaling MAPK/ERK and MAP kinase signaling cascades. Also the
mutated ANGPT2 is linked to PI3K-AKT and RAS signaling
pathways that it antagonizes. ANGPT2 is expressed in lympho-
cytes and controls T-cell proliferation. ANGPT2 and other
angiogenic factors are reportedly involved in chronic lymphocytic
leukemia where they exert pro-survival effects. Other STAT-
connected genes were receptors such as CD40LG (modulates
B-cell function, regulates immune system and participates in
STAT3 as well as in IL and NFAT signaling pathways) and FLT3 (a
class III receptor tyrosine kinase that promotes the phosphoryla-
tion of various proteins and kinases in the PI3K/AKT/mTOR, RAS
and JAK/STAT signaling pathways). Interestingly, CD40LG was
annotated in the same KEGG pathways as TNFAIP3 (Figure 2c),
which is a negative regulator of NF-κB signaling and known tumor
suppressor gene, and was recently found to be mutated in 8% of
T-LGL leukemia patients.15 Other relevant variants conﬁrmed in
STAT-mutation-negative patients and connected to the STAT
pathway were KRAS and the kinase KDR/VEGFR2.
Other components (and pathways) not directly linked to the
main lesions were also of interest. Nine genes were linked to cell
Figure 2. (a) Impact of selected somatic variants to protein products. Lollipop plots show the type and the position of somatic variants of four
selected genes in relation to the protein sequence and domain structure (see Supplementary Figure 5 for an extended version of the ﬁgure
including additional genes). The ADCY Tyr311* variant induces a very premature stop preventing the synthesis of the protein region including
Guanylate cyclase, ATP and Mg2+domains; FAT4 presents two variants, the high-impact missense variant Asp1485Asn in the Cadherin 14
domain and the frameshift variant Hys4261fs inducing a stop codon before Laminin G-like domain truncating the protein before the EGF-like
6 domain and the C terminal; ANGPT2 presents the high-impact missense variant Lys463Glu in Fibrinogen C-terminal domain implicated in
protein–protein interactions, and FLT3 shows a high-impact Asp228Gly variant. (b) Number of mutations per patient in each class. Normal
distribution of values was conﬁrmed with the Shapiro–Wilk test (P= 0.099). Both analysis of variance (P= 0.009) and pairwise Tukey s.d. post
hoc tests (P-values 0.010 and 0.019 in the comparisons of CD4+/CD4+CD8+ with NK and CD8+, respectively) conﬁrmed the statistical
signiﬁcance of the observed difference. (c) LGL leukemia mutation network. The network shows the functional relations of genes somatically
mutated in LGL leukemia patients, according to the integration of KEGG and Reactome pathway topology (see the text and Supplementary
Methods for details on the pathway-derived network reconstruction procedure); network nodes represent somatically mutated genes, node
color indicates recurrence (according to the legend heat color scale) in the cohort, node label indicates the gene Symbol (different label colors
indicates genes that are mutated only in STAT-mutation-positive (STAT+), only in STAT-mutation-negative (STAT− ) or in both patient groups,
as shown in the legend); genes are connected with black solid lines if they are directly connected in KEGG- and/or Reactome-derived
networks or with colored dashed lines if they participate in pathways including STAT3 and/or with STAT5B (see Supplementary Figure 6 for a
detailed version of the network).
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cycle regulation, and include the CDC25b gene and ATM, which is
involved in apoptosis and P53 signaling (Figure 2c). Furthermore,
the epigenetic nodule included the recurrently mutated KMT2D,
which is connected to ASH1L. Both are histone methyltransferases
involved in epigenetic regulation of gene expression programs
and are part of the ASCOM complex, involved in transcriptional
co-activation. The networks of genes mutated in individual CD8+
and CD4+ or NK LGL leukemia patients and in each patient
subgroup are presented in the Supplementary Figures 7–9.
To conclude, with the systems genetic approach, we were able
to map individual mutations found in LGL leukemia patients in
novel functional modules. The central role of JAK-STAT network
was further highlighted, and our data provide important new
insights of the activation of this pathway in those LGL leukemias
that do not carry STAT mutations.
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